The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Inclusions/Exclusions: Age >= 18 years, ECOG Performance Status 0-2, Triple Negative Breast Cancer, No stage IV (metastatic) breast cancer, No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed.
Learn More at ClinicalTrials.gov
Contact 310-582-7448 to participate.